OPV Pharmaceutical Joint Stock Company is proud to announce that it has been honored with two significant awards at the “2026 Famous Brand and Prestigious Quality Service” event — a double recognition that affirms the company’s unwavering commitment to quality, consumers, and the sustainable development of Vietnam’s pharmaceutical industry:

• STAR – Top 10 Products Committed to Consumer Interests 2026.
• OPV Pharmaceutical – Top 10 Exemplary Foreign-Invested Enterprises in Socio-Economic Development 2026.

The trophies and certificates from both prestigious awards received by OPV Pharmaceutical in 2026

STAR – Oral and Throat Care, Produced at OPV’s EU-GMP Certified Facility

The recognition of the STAR brand with the “Top 10 Products Committed to Consumer Interests 2026” award acknowledges OPV’s dedication to providing solutions that address daily oral and throat health needs — protecting and soothing the throat for the entire family.

A representative of OPV Pharmaceutical receiving the STAR Brand award for “Top 10 Products Committed to Consumer Interests 2026”

The STAR product line offers a diverse range of options for every member of the family:

• Star Sore Throat: a 3-in-1 formula that helps alleviate symptoms of sore throat and pharyngitis.
• Star Benko: effective for intensive oral and throat antisepsis, supporting oral care before and after surgery.
• Star Cough Relief: provides temporary relief for cough symptoms caused by throat irritation.
• Star Ivy: a syrup for children from 1 year old, formulated with dried ivy leaf extract to help reduce coughs and soothe the throat.
• Star Immune: lozenges combining Vitamin C and Zinc to help soothe the throat and boost daily resistance.

The STAR product portfolio — trusted oral and throat care for the whole family

With nearly 50 million lozenges distributed annually across more than 30,000 pharmacies nationwide, STAR has solidified its position as a trusted choice for consumers — with every product ensuring stability, safety, and high quality in each lozenge.

OPV Pharmaceutical – Connecting Long-standing Heritage with Global Quality Standards

Ms. Dao Thi Kim Loan, General Director of OPV, receiving the award for “Top 10 Exemplary Foreign-Invested Enterprises in Socio-Economic Development 2026”

This achievement is the result of the synergy between Vietnam’s foundational heritage and the management capabilities, investment, and global standards integrated since OPV became a member of the Singapore-based international pharmaceutical group, RV Group, in 2021.

With a history dating back to the 1950s, OPV Pharmaceutical remains patient-centric and consumer-focused, guided by the vision: “Real Value to Life Through Science.” OPV contributes to the development of Vietnam’s pharmaceutical industry while continuously enhancing the quality of community healthcare.

On this journey, the company has focused on upgrading its production facilities, quality management systems, and R&D capabilities to international standards. The OPV factory today holds international certifications including EU-GMP, WHO-GMP, and ISO, supported by a modern quality control system. The product portfolio has also been diversified — from well-known healthcare brands such as Ameflu, STAR, and Tydol to advanced specialized treatment lines, including oncology drugs, biological products, and next-generation healthcare solutions.

Looking Ahead

This 2026 double award serves as a powerful motivation for OPV to continue innovating, advancing pharmaceutical technology transfer, expanding international partnerships, and strengthening import-export activities — aiming to bring high-quality products to more markets within the region and across the globe.

We extend our sincere gratitude to our consumers, healthcare partners, distributors, and every member of the OPV family whose trust and dedication made these recognitions possible.